Tripathi M, Verma M, Gujrati V R, Palit G, Shanker K
Department of Pharmacology and Therapeutics, King George's Medical College, Lucknow, India.
Arzneimittelforschung. 1993 Jun;43(6):632-5.
3-(Benzylidene amino)-2-imino-4-thiazolidinones (IIa-c) synthesized by cyclization of substituted thiosemicarbazones (Ia-c) were converted into 2-amino-3-(substituted benzylamino)-4-thiazolidinones (IIIa-c), 2-imino-3-(alpha-aryl azo benzylidene) amino-4-thiazolidinones (IVa-f) and 2-(2-amino-4-oxo-3-thiazolidinyl)-3-aryl-4-isothiazolidinones (VIa-c), IVa-f were finally converted into 5-(arylamino methyl)-2-imino-3-(alpha-aryl azobenzylidene)-amino-4-thiazolidinones (Va-l). These compounds III, V and VI were evaluated for their monoamine oxidase (MAO) inhibitory activity in vitro and various CNS activities in vivo. Some of the compounds exhibited promising CNS activity.
通过取代硫代卡巴腙（Ia-c）环化合成的3-（亚苄基氨基）-2-亚氨基-4-噻唑烷酮（IIa-c）被转化为2-氨基-3-（取代苄基氨基）-4-噻唑烷酮（IIIa-c）、2-亚氨基-3-（α-芳基偶氮亚苄基）氨基-4-噻唑烷酮（IVa-f）和2-（2-氨基-4-氧代-3-噻唑烷基）-3-芳基-4-异噻唑烷酮（VIa-c），IVa-f最终被转化为5-（芳基氨基甲基）-2-亚氨基-3-（α-芳基偶氮亚苄基）-氨基-4-噻唑烷酮（Va-l）。对这些化合物III、V和VI进行了体外单胺氧化酶（MAO）抑制活性和体内各种中枢神经系统活性的评估。其中一些化合物表现出有前景的中枢神经系统活性。
